COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma

A new study provides preliminary evidence that tiotropium, a long-acting anticholinergic drug used for chronic obstructive pulmonary disease (COPD), is safe and effective in preschool-age children with asthma symptoms not well controlled by inhaled corticosteroids.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news

Related Links:

Effect of triple therapy in patients with asthma-COPD overlap
. Int J Clin Pharmacol Ther. 2019 Jun 24;: Authors: Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N, Tamaki T, Shimizu T, Nomura S Abstract OBJECTIVE: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inhaled corticosteroids, long-acting β2 agonists, and long-acting muscarinic antagonists. H...
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Abstract Corticosteroid insensitive airway inflammation is one of major barrier to effective managements of chronic airway diseases, such as obstructive pulmonary airway disease (COPD) and severe asthma. The role of nonreceptor tyrosine kinase Src is important in airway inflammation in mice models of atopic asthma and COPD. Thus, in this study, we determined the effects of Src inhibitor, dasatinib, on airway inflammation induced by repeated intranasal exposure to lipopolysaccharide (LPS). Male mice (A/J strain, 5 weeks old) were intranasally exposed to LPS twice daily for 3 days, and dasatinib was intranasally tre...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research
Authors: Oshagbemi OA, Franssen FME, van Kraaij S, Braeken DCW, Wouters EFM, Maitland-van der Zee AH, Driessen JHM, de Vries F Abstract Although recently introduced in the pharmacological treatment algorithm of chronic obstructive pulmonary disease (COPD), there is a need for more data supporting the use of blood eosinophil counts as a biomarker to guide inhaled corticosteroids (ICS) therapy. The aim of this study was to evaluate the risk of moderate and/or severe exacerbations and all-cause mortality in a large primary care population after withdrawal of ICS compared to continued users stratified by elevated blood...
Source: COPD: Journal of Chronic Obstructive Pulmonary Disease - Category: Respiratory Medicine Tags: COPD Source Type: research
Publication date: May–June 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 5Author(s): Richard H. Stanford, Carlyne Averell, Emily D. Parker, Cori Blauer-Peterson, Tyler K. Reinsch, Ami R. BuikemaBackgroundAlthough efficacy and safety of fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/F) have been demonstrated in clinical studies, real-world comparisons of utilization have not been performed.ObjectiveTo compare similar patients with asthma initiating FF/VI or BUD/F on measures of adherence, persistence, and the asthma medication ratio (AMR).MethodsThis wa...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Abstract Corticosteroid is the most widely used anti-inflammatory agent for asthma and chronic obstructive pulmonary disease (COPD). However, most of the severe asthmatics and COPD patients show poor response to the anti-inflammatory benefits of corticosteroids. Corticosteroid resistance is a major therapeutic challenge to the treatment of severe asthma and COPD. Cellular and molecular mechanisms underlying steroid insensitivity in severe asthma and COPD are still not fully understood. This review aims to recapitulate recent discoveries of potential contributing mechanisms of steroid resistance, and to appraise ne...
Source: Current Opinion in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Opin Pharmacol Source Type: research
Mario Malerba1,2*, Valentina Foci1,2, Filippo Patrucco1,2, Patrizia Pochetti1,2, Matteo Nardin3, Corrado Pelaia4 and Alessandro Radaeli5 1Respiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, Italy 2Respiratory Unit, Sant’Andrea Hospital, Vercelli, Italy 3Department of Medicine, Spedali Civili di Brescia, Brescia, Italy 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy 5Department of Emergency, Spedali Civili di Brescia, Brescia, Italy Chronic obstructiv...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Suissa and Ariel [1] performed a post hoc analysis of TRIBUTE and IMPACT [2, 3], by "digitising" the figures to obtain values over each month of the cumulative incidence curves. They concluded that the lower rate of a first exacerbation with triple long-acting muscarinic antagonist/long-acting β2-agonist/inhaled corticosteroid (LAMA/LABA/ICS) therapy was exclusively due to a lower rate in the first month of treatment, while the rates were comparable to LAMA/LABA in the subsequent 11 months. They argue that this pattern of "depletion of susceptible individuals" might identify a small group of p...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Correspondence Source Type: research
Authors: Lal C, Strange C Abstract INTRODUCTION: Inhaled corticosteroid/long-acting β-2 agonists (ICS/LABA) combination inhalers have been a lifeline for a generation of chronic obstructive pulmonary disease (COPD) and asthma patients. Fluticasone furoate and Vilanterol (FF/VI) as a once-daily ICS/LABA combination have an extensive clinical trial and real-world data to support its use in COPD patients. Areas covered: The authors provide pharmacological profiles of fluticasone furoate, vilanterol and the FF/VI fixed dose combination. Salient clinical trials evaluating efficacy and safety of the FF/VI combinatio...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
This study evaluated the effects of dried ginger and LGWWJX decoction on cold asthma at the metabolomics level. It provides a reference for the research on the compatibility of Chinese Medicine. Introduction Ginger is a Chinese medicine (CM) used as a food and as a medicine, and is often used to treat cold syndrome through the property of warming. Dried ginger (Zingiberis Rhizoma, GanJiang, GJ) is processed from fresh ginger and is also commonly used in CM. It is used to treat cold asthma by “warming the stomach to dispel cold, warming the lung to resolve fluid,” and it has significant anti-inflammatory...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion and Future Directions Above we reviewed a limited set of network medicine philosophies that seek to integrate biomedical big data to uncover meaningful biology. Network medicine approaches provide customized and optimized ways to leverage biomedical data. The choice of the appropriate network method is largely dictated by the underlying biological inquiry, hypotheses, study design, and available data. Although this review is not meant to be exhaustive, our intent was to give a essence of how biomedical data requires a nuanced approach when selecting network analyses and provide a resource for both network scien...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
More News: Asthma | Children | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Health | Spiriva | Study | Tiotropium